Management of post transplant hepatitis C in the direct antiviral agents era

Hepatology International

Volumn 9, Issue 2, 2015, Pages 192-201

  Coilly, Audrey ^a,b,c,d   Roche, Bruno ^a,b,c,d   Duclos Vallée, Jean Charles ^a,b,c,d   Samuel, Didier ^a,b,c,d  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

^d Hepatinov   (France)

Author keywords

Daclatasvir; Direct antiviral agents; Hepatitis C; Liver transplantation; Simeprevir; Sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; INTERFERON; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS; NS4 PROTEIN, HEPATITIS C VIRUS; OLIGOPEPTIDE; PROLINE; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VIRAL PROTEIN;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENT DISEASE; VIROLOGY;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; INTERFERONS; LIVER TRANSPLANTATION; OLIGOPEPTIDES; POSTOPERATIVE COMPLICATIONS; PROLINE; PROTEASE INHIBITORS; RECURRENCE; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84937764314     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-015-9621-5     Document Type: Review

References (63)

1. Charlton M, Ruppert K, Belle SH, Bass N, Schafer D, Wiesner RH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004;10(9):1120–1130
2. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32(4 Pt 1):852–858
3. Bizollon T, Pradat P, Mabrut JY, Chevallier M, Adham M, Radenne S, et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005;5(8):1909–1913
4. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008;49(2):274–287
5. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008;8(11):2426–2433
6. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195–1206
7. Jacobson IM, Mchutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405–2416
8. Burton JR Jr, O’leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014;61:508–514
9. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013;19(7):690–700
10. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014;60(1):78–86
11. Coilly A, Roche B, Duclos-Vallee JC, Samuel D. Management of HCV transplant patients with triple therapy. Liver Int 2014;34(Suppl 1):46–52
12. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, Ritonavir, ombitasvir, and dasabuvir achieves 97 and 100 % sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014;147:359–365
13. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370(21):1973–1982
14. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370(20):1889–1898
15. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370(16):1483–1493
16. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370(20):1879–1888
17. Kwo P, Mantry P, Coakley E, Te H, Vargas H. Results of the phase 2 study M12-999: interferon-free regimen of ABT-450/R/ABT 267 + ABT-333 + ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection. J Hepatol 2014;60:S47
18. Samuel D, Charlton M, Gane E, Brown R, Curry M. Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective multicenter study. J Hepatol 2014;60:S499
19. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation. Hepatology 2014. doi:10.1002/hep.27681
20. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008;14(Suppl 2):S36–S44
21. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122(4):889–896
22. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004;41(5):830–836
23. Berenguer M, Prieto M, San Juanf F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36(1):202–210
24. Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008;14(12):1766–1777
25. Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013;58(5):1028–1041
26. McCaughan G, Bowen DG. Pathogenesis of cholestatic hepatitis. J Hepatol 2011;54(392–39):4
27. Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011;53(1):317–324
28. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010;139(5):1577–1585, 85 e1-3
29. Humar A, Kumar D, Raboud J, Caliendo AM, Moussa G, Levy G, et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002;2(5):461–466
30. Duclos-Vallee JC, Feray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008;47:407–417
31. Zekry A, Whiting P, Crawford DH, Angus PW, Jeffrey GP, Padbury RT, et al. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transpl 2003;9(4):339–347
32. Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995;108:1088–1096
33. Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl 2003;9(11):S44–S47
34. Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011;17(12):1394–1403
35. Neumann U, Samuel D, Trunecka P, Gugenheim J, Gerunda GE, Friman S. A randomized multicenter study comparing a tacrolimus-based protocol with and without steroids in HCV-positive liver allograft recipients. J Transpl. 2012;2012:894215.
36. Chatterji U, Bobardt M, Selvarajah S, Yang F, Tang H, Sakamoto N, et al. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem 2009;284(25):16998–17005
37. Berenguer M. Recurrent hepatitis C: worse outcomes established, interventions still inadequate. Liver Transpl 2007;13(5):641–643
38. Irish WD, Arcona S, Bowers D, Trotter JF. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant 2011;11(8):1676–1685
39. Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009;15(7):782–789
40. Rabie R, Mumtaz K, Renner EL. Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis. Liver Transpl 2013;19(1):36–48
41. Curry MP, Forns X, Chung RT, Terrault NA, Brown R Jr, Fenkel JM, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015;148(1):100–107 e1
42. Mazzaferro V, Tagger A, Schiavo M, Regalia E, Pulvirenti A, Ribero ML, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001;33(1–2):1355–1357
43. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005;41(2):289–298
44. Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, et al. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011;17(5):528–538
45. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005;5(1):118–124
46. Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004;78(9):1308–1311
47. Carrion JA, Torres F, Crespo G, Miquel R, Garcia-Pagan JC, Navasa M, et al. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010;51(1):23–34
48. Blasco A, Forns X, Carrion JA, Garcia-Pagan JC, Gilabert R, Rimola A, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006;43(3):492–499
49. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006;6(7):1586–1599
50. Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008;15(10):699–709
51. Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013;33(Suppl 1):56–62
52. Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006;12(7):1067–1076
53. Berenguer M, Aguilera V, Prieto M, San Juanf F, Rayon JM, Benlloch S, Rayon JM, Benlloch S, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006;44(4):717–722
54. Forns X, Samuel D, Mutimer D, Fagiouli M, Navasa M. Interim SVR 12 results from the telaprevir phase 3B RELACE study in treatment naive stable liver transplant patients with genotype 1 HCV infection. J Hepatol 2014;60:S481
55. Coilly A, Furlan V, Roche B, Barau C, Noel C, Bonhomme-Faivre L, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother 2012;56(11):5728–5734
56. O’Leary JG, Mckenna GJ, Klintmalm GB, Davis GL. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. Liver Transpl 2013;19(4):463–465
57. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012;18(9):1053–1059
58. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013;13(6):1601–1605
59. Reddy KR, Everson GT, Flamm ST, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. Abstract AASLD 2014. Hepatology. 2014;60(supplement S1):200A.
60. Pungpapong S, Werner KT, Aquel B, et al. Multicenter experience using sofosbuvir and simeprevir with/without ribavirin to treat HCV genotype 1 after liver transplantation. Abstract AASLD 2014. Hepatology. 2014;60(supplement S1):201A.
61. Brown RS, Reddy KR, O’Leary JG, et al. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study. Abstract AASLD 2014. Hepatology. 2014;60(supplement s1):1269A.
62. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146(5):1176–92.
63. Curry M, Terrault N, O’leary J, Forns X, Brown R. Sofosbuvir plus ribavirin before transplantation prevented HCV infection post-transplantation in patients with HCV cirrhosis and HCC: results of an open-label trial. Liver Transpl. 2014;20(6 supplement 1):S150.